G

GSK

Develops medicines, vaccines, and consumer health

Portfolio Optimisation Director - Alliance Markets

Full-TimeUpdated Deadline 11/11/26
No salary listed
Expert
Master's
London, UK
HybridLondon HQ; hybrid, with two to three days onsite per week. No flexibility on UK location.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • Significant experience in commercial roles, sales, access, pricing, tender and loss-of-exclusivity or related roles in pharmaceuticals.
  • Strong strategic thinking and structured problem-solving, with the ability to translate complex market and financial data into actionable strategies.
  • Stakeholder management skills within a complex, cross-functional and cross-company matrix structure.
  • Ability to construct and assess pricing options, challenge assumptions, and drive value-based outcomes with country teams.
  • Collaboration and influencing skills, with a track record of driving alignment and execution across diverse stakeholders and geographies.
Responsibilities
  • Lead the development and execution of strategies to optimise the product and project portfolio, balancing risk, opportunity, and resources; lead the loss-of-exclusivity strategy, keeping performance ahead of plan and anticipating risks and opportunities.
  • Review, challenge, and refine country business cases and tenders related to DTG, ensuring alignment with regional and global strategy and financial targets.
  • Lead pricing option development and scenario modelling, support local operating companies with tender negotiation, and consolidate recommendations for review and decision by global and local stakeholders in partnership with finance, pricing, market access, and commercial teams.
  • Partner with global and local finance, pricing, market access, and commercial teams on robust financial assessments of proposals, including margin, volume, and competitive impact.
  • Build and maintain a holistic view of loss-of-exclusivity status, pricing dynamics, the competitive landscape, and tender timelines across the Alliance region, translating insights into strategic actions.
  • Coordinate and influence cross-functional and cross-company stakeholders in a matrix environment to secure alignment on optimisation strategies and implementation plans.
  • Act as the central point of contact for countries on loss-of-exclusivity optimisation, ensuring two-way communication of guidance, expectations, and feedback.
  • Present optimisation proposals and scenarios to senior stakeholders, including rationale, financial impact, risks, and trade-offs, in written and verbal formats.
  • Monitor implementation and performance of agreed optimisation strategies, identify deviations from plan, and drive corrective actions.
  • Contribute to portfolio optimisation beyond loss of exclusivity, including lifecycle management, channel and mix optimisation, and contract structures.
Desired Qualifications
  • Postgraduate degree in business, finance, life sciences, or a related discipline.
  • Financial acumen, including experience with business case evaluation, pricing scenarios, tender assessments, and profit-and-loss implications.
  • Written and verbal communication skills, including the ability to articulate proposals developed for countries and proposals received from them, tailoring messages to different seniority levels.
  • Experience proactively managing loss of exclusivity or similar high-impact market transitions to outperform plan.
  • Experience in pricing, market access, or commercial roles.
  • Ability to remain resilient under pressure and operate with ambiguity, making recommendations with incomplete data.
  • Integrity, accountability, and ownership of outcomes.
  • Ability to challenge constructively while maintaining strong partnerships.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.